1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1233 articles with Genentech, Inc.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance...
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain
Genentech’s Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases
Convelo Therapeutics Enters Into Collaboration and Option to Acquire Agreement With Genentech to Discover Novel Remyelinating Therapies
The collaboration will build on the remyelinating targets and proprietary screening platform developed by Convelo’s scientific founders Drs Paul Tesar and Drew Adams.
Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases
Skyhawk will use its SkySTARTM platform to develop drug candidates directed to multiple targets for oncology and neurodegenerative diseases.
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech veteran Marcel van der Brug, who is the chief scientific officer for therapeutics.
Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases
Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases
Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress
New analyses from Phase III HAVEN studies support Hemlibra’s sustained efficacy, safety and quality of life benefit in people with hemophilia A, with and without factor VIII inhibitors
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years
Genentech, a Roche company, announced that its Phase III MINISTONE-2 clinical trial hit its primary endpoint, showing that its Xofluza (baloxavir marboxil) was comparable to its own Tamiflu (oseltamivir). It was also well-tolerated in children with the flu.
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
Genentech, a member of the Roche Group, announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).
Genentech announced positive topline results from its Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug mycophenolate mofetil in patients with pemphigus vulgaris.
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application and granted Priority Review for the use of Rituxan®, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older.